Abstract:Abstract Background Lung cancer in very young adults in China aged <30 is on the rise and the clinicopathological characteristics of this unique population are incomplete and are yet to be elucidated. Our study aims to explore the characteristics, trends and distinctive features of lung cancer this age group to provide more information that can aid in developing optimal treatment regimens and improve prognosis for this exclusive age group. Method A retrospective review of 141 lung cancer patients admitted at our hospital from August 2011 to October 2021 was performed. The focused age group in our study was 18-30 years old. The data collected included demographics, tumor pathology, gene mutations, and treatment. Overall survival and prognosis were systematically analyzed. Results From a total of 141 of young lung cancer patients, 139 were included in final analysis. The gender distribution in our series favored female(65.5%), and only 7.2% of the study cohort had a history of smoking. Adenocarcinoma was the most common histological type in our study, presenting 93.5% of all patients. The most common stages at diagnosis was stage I(61.2%) and stage IV(30.2%). Genetic testing was performed in only 24.5% (34/139) of the patients. From the 23/34 patients in our study who tested positive for a genetic mutation, 19 (82.3%) were stage IV. The most common gene mutation was Anaplastic Lymphoma kinase(ALK) rearrangement observed in 13/23 (56.5%) gene mutation positive patients. Among stage IV NSCLC, OS was longer in patients who received targeted therapy, compared to the patients not receiving target therapy: 88 months vs 24 months (95% CI: 0.15-1.0, p=0.0282). Conclusion Lung cancer in the young adult population has particular characteristics (Common in female, non-smoker and adenocarcinoma patients). Higher stages of disease were observed in those with a gene mutation (notably ALK rearrangement). Although the sample size was small, the current data suggests a higher mutation rate in the younger population. These findings have fundamental implications for practice and we propose that all patients under 30 diagnosed with lung cancer should undergo genetic testing so they can receive personalized treatment and therefore achieve better outcomes.

[The clinical analysis of 469 pulmonary carcinomatous cases diagnosed by bronchoscopy under the age of 40.].

Comparison between young and old patients with lung cancer

Clinicopathologic and prognostic studies on young male with lung adenocarcinoma

The Analysis of Clinical and Pathological Characteristics of 217 Young Patients with Lung Cancer

Retrospective Analysis of 1470 Cases with Lung Cancer Diagnosed by Fibrobronchoscopy

The clinical features of breast cancer in young patients

Demographics, Risk Factors and Survival Analysis of Lung Cancer in Young Adults (&lt;30 Years) in China-A Retrospective Cohort Study

Clinical and Pathological Features of Pulmonary Carcinoma Patients under 40

Clinical Study of Young Patients Compared with Middle and Old Aged Lung Cancer Patients Diagnosed by Bronchoscope

Values of Fibrobronchoscopy to the Diagnosis of Lung Cancer in Teenager Patients

Clinical analysis of 118 young patients with lung cancer

Clinicopathological Characteristics and Prognosis of Lung Cancer in Young Patients Aged 30 Years and Younger.

[Analysis of Bronchoscopy Characteristics for 729 Female Patients with Lung Cancer.].

Analysis of clinical and pathological features of young patients with lung cancer

Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger

CLINICAL STUDY OF PR IMARY LUNG CANCER IN YOUNG PATIENTS

Analysis of the Molecular and Clinicopathologic Features of Surgically Resected Lung Adenocarcinoma in Patients under 40 Years Old.

Characteristics and Prognostic Analysis of 60 Young Patients with Lung Cancer

Clinical analysis on 484 young patients with pulmonary carcinoma

Outcome and Prognosis for Patients Younger Than Thirty with Primary Lung Cancer.

Unique Clinicopathological Characteristics and Favorable Prognosis of Young Patients with Non-Small Cell Lung Cancer